Study of CGT4255 for advanced solid tumors with HER2 changes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed advanced solid tumor that has spread or cannot be removed by surgery.
- Your tumor must have a specific HER2 gene change, NRG1 fusion, or HER2 protein overexpression.
- Your cancer must be measurable on scans.
- You must be in good enough health to carry out daily activities (ECOG score 0-1 or 0-2 depending on the part).
- Your blood tests must be within acceptable ranges.
- You cannot have had certain cancer treatments or major surgeries within a few weeks before starting the study drug.
- You must not have significant heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
This trial tests a new drug, 3HP-327, for people with advanced solid tumors that have certain changes in the FGFR2 gene and have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug (YH42946) in people with advanced solid tumors that have specific changes in HER2 or EGFR genes and have stopped responding to standard therapies. The drug aims to target these genetic changes to slow or shrink the cancer. Participants will be monitored closely for safety and how well the drug works.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This trial tests an investigational drug (SHR-4602) alone or with other treatments for advanced solid tumors that have HER2. The goal is to see if it can shrink or control the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.